Welcome to our dedicated page for Canopy Growth news (Ticker: CGC), a resource for investors and traders seeking the latest updates and insights on Canopy Growth stock.
Canopy Growth Corporation develops and sells cannabis products for adult-use and medical markets, with common shares trading as CGC on Nasdaq and WEED on the TSX. Company updates frequently cover Canadian brand activity across Tweed, Deelish, 7ACRES, DOJA, Deep Space and related formats including flower, pre-rolls, vapes, softgels and minor cannabinoid products.
News also centers on medical cannabis services through Canada House Clinics and the Abba Medix online channel, Storz & Bickel vaporization devices, operating and financial results, capital-structure actions, shareholder voting matters and governance changes. Canopy Growth also discloses its unconsolidated, non-controlling interest in Canopy USA as exposure to the U.S. THC market.
Canopy Growth Corporation (CGC) will release its financial results for Q4 and fiscal year 2022 on May 27, 2022. The release will occur before market open, and a subsequent audio webcast featuring CEO David Klein and CFO Judy Hong will take place at 10:00 AM ET the same day. For the first time, shareholders can engage via a Q&A platform managed by Say Technologies, opening on May 20 and closing on May 26. The company has a strong market presence, offering diverse cannabis products, including oils and edibles, and is partnered with Constellation Brands.
Canopy Growth Corporation (CGC) announced strategic initiatives aimed at reducing costs and enhancing profitability, targeting savings of $100-$150 million within 12-18 months. Key actions include reducing cost of goods sold (COGS) through improved efficiency, implementing flexible manufacturing, and streamlining indirect costs. The company anticipates charges of $250-$300 million in Q4 FY2022 primarily due to non-cash impairments. Management emphasizes the critical need for these changes to align with market realities and support long-term growth.
Canopy Growth Corporation (CGC) announced key leadership appointments to bolster strategic growth and execution for FY23. Judy Hong becomes Chief Financial Officer, bringing over 20 years of financial experience, while Jonathan Di Tosto steps in as Chief Operations Officer, focusing on optimizing the supply chain. Four new strategic roles were created in the Senior Leadership Team to enhance U.S. operations, leveraging partnerships with Constellation Brands. CEO David Klein emphasized the importance of this new leadership structure as Canopy aims for increased profitability and market positioning.
Canopy Growth Corporation (NASDAQ: CGC) announced positive results from a six-month clinical trial exploring the effects of cannabidiol (CBD) on menstrual-related symptoms. Conducted with James Madison University, the study involved 40 participants who received either 160mg or 320mg of CBD for 5 days each month. Results showed significant reductions in symptoms such as cramping, irritability, and stress. This research highlights the potential of cannabis-based therapies in managing menstrual health, paving the way for future studies on CBD's effects throughout reproductive life stages.
Benzinga announced that Canopy Growth CEO David Klein and Wana Brands CEO Nancy Whiteman will keynote the Benzinga Cannabis Capital Conference on April 20-21, 2022, in Miami, Florida. They will discuss effective strategies for entering the U.S. THC market amid evolving regulations. Klein emphasized building a robust U.S. ecosystem through partnerships, while Whiteman highlighted Wana's growth and innovative approaches. The conference promises extensive networking, a new expo floor, and opportunities for investment capital.
Martha Stewart CBD has expanded its product lineup with the launch of Tropical Medley CBD Wellness Gummies, featuring new flavors: Alphonso Mango, Coconut, and Pineapple. The gummies, made with 100% hemp-derived CBD isolate, aim to enhance consumer wellness experiences. Available in three sizes, prices range from $3.99 to $34.99, with online sales starting March 14, 2022. This launch reflects Canopy Growth's commitment to delivering high-quality CBD products and supports Martha Stewart's partnership with the company, enhancing brand visibility and market reach.
Canopy Growth Corporation (NASDAQ: CGC) announced its participation as Silver Sponsor at Natural Products Expo West 2022, taking place from March 8-12 in Anaheim, CA. The company will showcase its CBD brands, including Martha Stewart CBD and Quatreau, highlighting innovations in CBD wellness products. An industry panel, "Cannabis Evolution: The Latest Innovations and Trends in CBD and Wellness," will occur on March 10, featuring notable speakers from Canopy Growth and the CBD industry. The event aims to address consumer wellness needs through diverse CBD offerings.
Canopy Growth Corporation (CGC) reported its Q3 fiscal 2022 results, showing a 7% sequential revenue growth but an 8% decline year-over-year to $141 million. The cannabis revenue decreased by 20% while other consumer products, particularly BioSteel, saw a 130% increase in revenue. The company is focusing on reducing operating expenses, targeting profitability in Canada, and expanding its U.S. CBD and THC strategies. Despite a net loss of $115 million, it maintained a strong cash position of $1.4 billion. Actions are underway to enhance execution in the Canadian market.
Canopy Growth Corporation (NASDAQ: CGC) will announce its financial results for Q3 FY 2022 on February 9, 2022. The results will cover the period ending December 31, 2021, and a live audio webcast will follow at 10:00 AM ET the same day, featuring CEO David Klein and Interim CFO Judy Hong. Stakeholders can access a replay of the webcast until May 10, 2022. The company continues to expand its diverse cannabis and cannabinoid products, focusing on quality and customer relationships across various markets.
Martha Stewart CBD has launched a new line of CBD Wellness Topicals, marking its first category expansion. The product range includes Super Strength CBD Cream for muscle recovery, Sleep Science CBD Cream for sleep enhancement, and Daily De-Stress CBD Cream for stress management. Each cream is formulated with high CBD levels and innovative aroma-technology. The products are available in various sizes and competitively priced, with the goal of making wellness accessible and effective. This expansion is a collaborative effort with Canopy Growth Corporation.